Research Article
The Impact of Hyperoxia on Outcome of Patients Treated with Noninvasive Respiratory Support
Table 2
Hyperoxic and normoxic patient profiles.
| | Hyperoxia group n = 62 | Normoxia group n = 125 | value |
| Age (years) | 68.3 ± 17.5 | 68.6 ± 14.8 | >0.05 | APACHE II | 15.7 ± 6.7 | 16.3 ± 6.6 | >0.05 | Highest PaO2 (mmHg) | 131.1 ± 55.5 | 101.2 ± 43.9 | <0.001 | IMV days (n = 24/48) | 13.5 ± 41.1 | 25.9 ± 61.1 | >0.05 | ICU stay (days) | 11.8 ± 25.8 | 12.7 ± 22.6 | >0.05 | Hospital stay (days) | 33.6 ± 42.3 | 28.9 ± 33.1 | >0.05 | Gender (f/m) | 36/26 | 63/62 | >0.05 | Comorbidities (n, %) | | | | COPD | 10 (16.1) | 44 (35.2) | <0.02 | CHD | 12 (19.4) | 27 (21.6) | >0.05 | CHF | 12 (19.4) | 28 (22.4) | >0.05 | CRF | 12 (19.4) | 20 (16.0) | >0.05 | HT | 31 (50.0) | 70 (56.0) | >0.05 | DM | 17 (27.4) | 42 (33.6) | >0.05 | CLF | 8 (12.9) | 5 (4.0) | <0.04 | Malignancy | 22 (35.5) | 34 (27.2) | >0.05 | Dementia | 4 (6.5) | 4 (3.2) | >0.05 | IMV required (n, %) | 24 (38.7) | 48 (38.4) | >0.05 | ICU mortality (n, %) | 18 (29.0) | 38 (30.4) | >0.05 | Hospital mortality (n, %) | 32 (51.6) | 44 (35.2) | <0.04 | O2 treatment modality (n, %) | | | | Oxygen supply/NIMV | 34/28 | 43/82 | <0.008 |
|
|
COPD: chronic obstructive pulmonary disease, CHD: coronary heart disease, CHF: congestive heart failure, CRF: chronic renal failure, HT: hypertension, DM: diabetes mellitus, and CLF: chronic liver failure.
|